成年期血管风险与晚年脑病理的关联:英国出生队列研究
该前瞻性队列研究纳入463名1946年出生的参与者,评估36岁、53岁和69岁时血管风险与晚年脑结构及病理的关联。结果显示各时点血管风险均与全脑体积较小和 white matter-hyperintensity 体积较高相关,36岁时效应最大,但与β-淀粉样蛋白状态无关。提示早期成年期血管风险对晚年脑健康影响显著。
要点
- 成年期各阶段血管风险均与晚年全脑体积较小和 white matter-hyperintensity 体积较高相关。
- 36岁(早期成年)血管风险与晚年脑影像指标的关联效应最大。
- 未发现血管风险与β-淀粉样蛋白沉积相关的证据,至少至71岁。
核心结论
- 较高的血管风险与69至71岁时全脑体积较小和 white matter-hyperintensity 体积较高相关。
- 早期成年期血管风险与晚年脑影像指标的关联最强。
- 无证据表明较高血管风险影响β-淀粉样蛋白沉积,至少至71岁。
- 建议从早期成年期开始通过适当干预降低血管风险以最大化晚年脑健康。
研究设计与样本
- 前瞻性纵向队列研究(Insight 46),隶属1946年启动的英国医学研究理事会全国健康与发育调查。
- 共502名参与者接受评估,463名(236名男性,51.0%)符合纳入标准并纳入分析。
- 血管风险因素在36岁、53岁和69岁时评估,影像学评估于2015年5月至2018年1月进行。
- 影像学检查包括多模态磁共振成像和florbetapir-淀粉样蛋白正电子发射断层扫描。
- 暴露为基于Framingham心脏研究-心血管风险评分(FHS-CVS),使用收缩压、降压药使用、吸烟、糖尿病状态和体重指数计算。
主要发现
- FHS-CVS随年龄增长:36岁中位数2.7%(IQR 1.5%-3.6%),53岁10.9%(6.7%-15.6%),69岁24.3%(14.9%-34.9%)。
- 各时点FHS-CVS均与全脑体积较小相关:36岁β系数每1%增加为-3.6(95%CI -7.0至-0.3),53岁-0.8(95%CI -1.5至-0.08),69岁-0.6(95%CI -1.1至-0.2)。
- 各时点FHS-CVS均与 white matter-hyperintensity 体积较高相关:36岁指数化系数1.09(95%CI 1.01-1.18),53岁1.02(95%CI 1.00-1.04),69岁1.01(95%CI 1.00-1.02)。
- 效应量在36岁时最大。
- 任何时点FHS-CVS均与β-淀粉样蛋白状态无关。
关键数值与推荐
- β-淀粉样蛋白状态通过灰质/侵蚀性皮层下白质标准化摄取值比值阈值0.61判定。
- 影像学评估时平均(SD)年龄为70.7(0.7)岁,β-淀粉样蛋白阳性者83例(18.2%)。
- 分析模型调整了影像学检查时年龄、性别、APOE基因型、社会经济地位,并在适当情况下调整总颅内体积。
临床怎么用
- 临床应关注早期成年期血管风险因素的评估与管理,以降低晚年脑结构损伤风险。
- 血管风险干预可能有助于减少 white matter-hyperintensity 体积和全脑萎缩,但对淀粉样蛋白病理可能无直接影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Midlife vascular risk burden is associated with late-life dementia. Less is known about if and how risk exposure in early adulthood influences late-life brain health. OBJECTIVE: To determine the associations between vascular risk in early adulthood, midlife, and late life with late-life brain structure and pathology using measures of white matter-hyperintensity volume, β-amyloid load, and whole-brain and hippocampal volumes. DESIGN, SETTING, AND PARTICIPANTS: This prospective longitudinal cohort study, Insight 46, is part of the Medical Research Council National Survey of Health and Development, which commenced in 1946. Participants had vascular risk factors evaluated at ages 36 years (early adulthood), 53 years (midlife), and 69 years (early late life). Participants were assessed with multimodal magnetic resonance imaging and florbetapir-amyloid positron emission tomography scans between May 2015 and January 2018 at University College London. Participants with at least 1 available imaging measure, vascular risk measurements at 1 or more points, and no dementia were included in analyses. EXPOSURES: Office-based Framingham Heart study-cardiovascular risk scores (FHS-CVS) were derived at ages 36, 53, and 69 years using systolic blood pressure, antihypertensive medication usage, smoking, diabetic status, and body mass index. Analysis models adjusted for age at imaging, sex, APOE genotype, socioeconomic position, and, where appropriate, total intracranial volume. MAIN OUTCOMES AND MEASURES: White matter-hyperintensity volume was generated from T1/fluid-attenuated inversion recovery scans using an automated technique and whole-brain volume and hippocampal volume were generated from automated in-house pipelines; β-amyloid status was determined using a gray matter/eroded subcortical white matter standardized uptake value ratio threshold of 0.61. RESULTS: A total of 502 participants were assessed as part of Insight 46, and 463 participants (236 male [51.0%]) with at least 1 available imaging measure (mean [SD] age at imaging, 70.7 [0.7] years; 83 β-amyloid positive [18.2%]) who fulfilled eligibility criteria were included. Among them, FHS-CVS increased with age (36 years: median [interquartile range], 2.7% [1.5%-3.6%]; 53 years: 10.9% [6.7%-15.6%]; 69 years: 24.3% [14.9%-34.9%]). At all points, these scores were associated with smaller whole-brain volumes (36 years: β coefficient per 1% increase, -3.6 [95% CI, -7.0 to -0.3]; 53 years: -0.8 [95% CI, -1.5 to -0.08]; 69 years: -0.6 [95% CI, -1.1 to -0.2]) and higher white matter-hyperintensity volume (exponentiated coefficient: 36 years, 1.09 [95% CI, 1.01-1.18]; 53 years, 1.02 [95% CI, 1.00-1.04]; 69 years, 1.01 [95% CI, 1.00-1.02]), with largest effect sizes at age 36 years. At no point were FHS-CVS results associated with β-amyloid status. CONCLUSIONS AND RELEVANCE: Higher vascular risk is associated with smaller whole-brain volume and greater white matter-hyperintensity volume at age 69 to 71 years, with the strongest association seen with early adulthood vascular risk. There was no evidence that higher vascular risk influences amyloid deposition, at least up to age 71 years. Reducing vascular risk with appropriate interventions should be considered from early adulthood to maximize late-life brain health.
引用
- Lane CA, Barnes J, Nicholas JM, et al. Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life: Evidence From a British Birth Cohort. JAMA Neurol. 2020. PMID: 31682678. doi:10.1001/jamaneurol.2019.3774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。